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Abstract
Insulin autoimmune syndrome (IAS) is a rare cause of spontaneous hypoglycemia in which insulinantibody complexes circulate in abundance. The pathophysiology and optimal treatment remain unclear. Here we describe a case with novel adverse cardiovascular features where B-cell depletion with rituximab led to resolution of dysglycemia and this vascular phenotype.
History & Examination
A 37 year-old female presented to the emergency department having collapsed; venous glucose measured 50mg/dL. She reported recurrent dizziness since the birth of her fifth child 10 months previously and had . During several of these she recorded low capillary blood glucose (36-52mg/dL) when symptomatic. Her past history included gestational diabetes during the most recent pregnancy, treated with insulin aspart (NovoRapid ® ), insulin glargine (Lantus ® ) and metformin.
These therapies had been discontinued 1 month post-partum.
Investigation
Blood count and renal, liver, thyroid and adrenal function were all normal. HbA 1c was 41mmol/mol (5.9%). A cContinuous glucose monitoring system (CGMS) demonstrated early-morning (asymptomatic) hypoglycemia and post-prandial hyperglycemia. During hypoglycemia she had high circulating insulin (39,181pmol/L; C-peptide 1,046pmol/L). Insulin assay was performed as previously described.(1) Only 4% of total immunoreactive insulin was recovered from plasma supernatant following polyethylene glycol precipitation, consistent with the presence of high molecular-weight insulin immunoreactivity. Insulin eluted from a gel filtration column predominantly in high molecular-weight fractions (Figure) ; exogenous insulin exchange was employed to refute heterophilic antibody assay interference and confirm the presence of insulinantibody complexes ('macroinsulin').(1) Serum anti-insulin IgG concentration was 171mg/L (0-5).
We diagnosed insulin autoimmune syndrome (IAS), a term commonly used in patients without previous exposure to exogenous insulin. Here, we cannot exclude that the insulin antibodies 3 generated were in response to exogenous insulin, but severe hypoglycemia did not develop until many months after cessation of insulin therapy. Moreover, aAntibodies developing following after exposure to exogenous insulin rarely bind insulin with sufficient capacity or affinity to perturb glycemia.(2) Here, we cannot exclude that the insulin antibodies generated were in response to exogenous insulin, but severe hypoglycemia did not develop until many months after insulin therapy stopped and the post-partum presentation is typical for recrudescence, or first appearance, of autoimmune disease.
The patient was fitted with a CGMS with hypoglycemia alarm and prescribed a diet comprising of frequent low glycemic-index carbohydrate meals. As sSignificant hypoglycemia continued. Thus, prednisone was commenced at (1mg/kg/day) and titrated according to CBG readings and symptoms to 10mg/day over three months. To reduce anti-insulin antibodies, we gave the anti-CD20 monoclonal antibody rituximab was administered.
A rRepeat CGM after six weeks revealed intermittent hypoglycemia and sustained daytime hyperglycemia. Over months, there were reductions in total insulin, anti-insulin antibody concentration and antibody-bound insulin (Figure) . These were associated with reduced hypoglycemia and iimprovedmprovement in hypoglycemic awareness. By 6 months, hypoglycemia was rare and post-prandial hyperglycemia had improved (CGM peak glucose on CGMS 162.0mg/dL). There were no adverse events and prednisone was discontinued after 10 months, following after which no further hypoglycemia was recorded.
Recurrent hypoglycemia (in type I diabetes mellitus) is associated with endothelial dysfunction, inflammation and increased cardiovascular risk.(3) In other contexts, rituximab has been shown to improve measures of endothelial function.(4) Thus, we explored the cardiovascular phenotype associated with IAS, before and after treatment. Carotid-femoral pulse wave velocity (PWV) was 7.6m/s at presentation and 5.2m/s at 6 months (5.2-8.0m/s); there was no change in blood pressure over this period. This suggests elevated arterial stiffness at presentation , and is associated with 4 cardiovascular risk.(4) Other surrogate markers of endothelial dysfunction Plasma ADMA (an endogenous inhibitor of nitric oxide biosynthesis), endothelin-1 (a potent vasoconstrictor) and urate (associated with arterial stiffness and cardiovascular risk) were all higher at disease presentation than at 6 months ( Figure) . Circulating levels of miR-126 rose following treatment (Figure) . This microRNA is endothelial-enriched and is considered thought to maintain endothelial homeostasis and promote vasculogenesis.(4) There was minimal change in control miR-122-5p.
Conclusions
Treatment of IAS is poorly defined. Historically, glucocorticoids and plasmapharesis were used for refractory cases. We show that B-cell depletion with rituximab induces a sustained reduction in anti-insulin antibodies, circulating insulin and the frequency of hypoglycemia. Rituximab has been used successfully in two other cases of IAS. (5, 6) However in one, concomitant use of plasmapheresis, methotrexate and intravenous immunoglobulin make it difficult to ascribe the beneficial therapeutic effect solely to rituximab.
Our report is novel in providing We also present data to suggesting an adverse vascular phenotype in IAS that is reversible when dysglycemia resolves. We speculate that recurrent hypoglycemiadysglycemia , hyperglycemia and circulating immune complexes may contribute to vascular dysfunction in IAS, but further study is required to determine the underlying mechanism, and how treatment improves vascular health.
History & Examination
A 37 year-old female presented to the emergency department having collapsed; venous glucose measured 50mg/dL. She reported recurrent dizziness since the birth of her fifth child 10 months previously and had recorded low capillary blood glucose (36-52mg/dL) when symptomatic. Her past history included gestational diabetes during the most recent pregnancy, treated with insulin aspart, insulin glargine and metformin. These therapies had been discontinued 1 month post-partum.
Investigation
Blood count and renal, liver, thyroid and adrenal function were all normal. HbA 1c was 41mmol/mol We diagnosed insulin autoimmune syndrome (IAS), a term commonly used in patients without previous exposure to exogenous insulin. Here, we cannot exclude that the insulin antibodies generated were in response to exogenous insulin, but severe hypoglycemia did not develop until many months after cessation of insulin therapy. Moreover, antibodies developing after exposure to exogenous insulin rarely bind insulin with sufficient capacity or affinity to perturb glycemia. (2) The patient was fitted with CGM with hypoglycemia alarm and prescribed a diet of frequent low glycemic-index carbohydrate meals. As significant hypoglycemia continued, prednisone was commenced (1mg/kg/day) and titrated according to CBG readings to 10mg/day over three months.
To reduce anti-insulin antibodies, we gave the anti-CD20 monoclonal antibody rituximab.
Repeat CGM after six weeks revealed intermittent hypoglycemia and sustained daytime hyperglycemia. Over months, there were reductions in total insulin, anti-insulin antibody concentration and antibody-bound insulin (Figure) . These were associated with reduced hypoglycemia and improved hypoglycemic awareness. By 6 months, hypoglycemia was rare and post-prandial hyperglycemia had improved (CGM peak glucose 162.0mg/dL). There were no adverse events and prednisone was discontinued after 10 months, after which no further hypoglycemia was recorded.
Recurrent hypoglycemia is associated with endothelial dysfunction, inflammation and increased cardiovascular risk.(3) Thus, we explored the cardiovascular phenotype associated with IAS, before and after treatment. Carotid-femoral pulse wave velocity (PWV) was 7.6m/s at presentation and 5.2m/s at 6 months (5.2-8.0m/s); there was no change in blood pressure over this period. This suggests elevated arterial stiffness at presentation, associated with cardiovascular risk. Other surrogate markers of endothelial dysfunction were all higher at disease presentation than at 6 months ( Figure) . Circulating miR-126 rose following treatment (Figure) . This microRNA is endothelial-enriched and is thought to maintain endothelial homeostasis and promote vasculogenesis.(4) There was minimal change in control miR-122-5p.
Conclusions
Treatment of IAS is poorly defined. Historically, glucocorticoids and plasmapharesis were used for refractory cases. We show that B-cell depletion with rituximab induces a sustained reduction in anti-insulin antibodies, circulating insulin and the frequency of hypoglycemia. Rituximab has been used successfully in two other cases of IAS. (5, 6) However in one, concomitant use of plasmapheresis, methotrexate and intravenous immunoglobulin make it difficult to ascribe the beneficial therapeutic effect to rituximab.
Our report is novel in providing data to suggest an adverse vascular phenotype in IAS that is reversible when dysglycemia resolves. We speculate that recurrent dysglycemia may contribute to vascular dysfunction in IAS, but further study is required to determine the underlying mechanism. 
